Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds

Confirms Sigma-1 Receptor Implicated in Targeting Depression, Anxiety, Epilepsy and Brain Injury after Ischemic Stroke New York – June 30, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of…